vs
Amneal Pharmaceuticals, Inc.（AMRX）与Liberty Energy Inc.（LBRT）财务数据对比。点击上方公司名可切换其他公司
Liberty Energy Inc.的季度营收约是Amneal Pharmaceuticals, Inc.的1.3倍（$1.0B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs 2.2%，领先2.1%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs 4.5%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs -6.2%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Liberty Energy Inc.是北美领先的能源服务供应商，专注为油气运营企业提供水力压裂及完井解决方案，服务覆盖美国主要页岩产区，供应低排放作业设备及定制化支持，帮助提升油气井生产效率。
AMRX vs LBRT — 直观对比
营收规模更大
LBRT
是对方的1.3倍
$814.3M
营收增速更快
AMRX
高出7.0%
4.5%
净利率更高
AMRX
高出2.1%
2.2%
两年增速更快
AMRX
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.0B |
| 净利润 | $35.1M | $22.6M |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | 2.2% |
| 净利率 | 4.3% | 2.2% |
| 营收同比 | 11.5% | 4.5% |
| 净利润同比 | 212.9% | 64.8% |
| 每股收益（稀释后） | $0.10 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXLBRT
| Q1 26 | — | $1.0B | ||
| Q4 25 | $814.3M | $1.0B | ||
| Q3 25 | $784.5M | $947.4M | ||
| Q2 25 | $724.5M | $1.0B | ||
| Q1 25 | $695.4M | $977.5M | ||
| Q4 24 | $730.5M | $943.6M | ||
| Q3 24 | $702.5M | $1.1B | ||
| Q2 24 | $701.8M | $1.2B |
净利润AMRXLBRT
| Q1 26 | — | $22.6M | ||
| Q4 25 | $35.1M | $13.7M | ||
| Q3 25 | $2.4M | $43.1M | ||
| Q2 25 | $22.4M | $71.0M | ||
| Q1 25 | $12.2M | $20.1M | ||
| Q4 24 | $-31.1M | $51.9M | ||
| Q3 24 | $-156.0K | $73.8M | ||
| Q2 24 | $6.0M | $108.4M |
毛利率AMRXLBRT
| Q1 26 | — | — | ||
| Q4 25 | 36.5% | 20.6% | ||
| Q3 25 | 34.9% | 18.7% | ||
| Q2 25 | 39.5% | 22.1% | ||
| Q1 25 | 36.8% | 22.1% | ||
| Q4 24 | 36.0% | 21.4% | ||
| Q3 24 | 38.4% | 26.2% | ||
| Q2 24 | 35.6% | 27.9% |
营业利润率AMRXLBRT
| Q1 26 | — | 2.2% | ||
| Q4 25 | 13.8% | 1.9% | ||
| Q3 25 | 9.0% | -0.3% | ||
| Q2 25 | 15.4% | 3.6% | ||
| Q1 25 | 14.4% | 1.9% | ||
| Q4 24 | 10.4% | 2.6% | ||
| Q3 24 | 12.6% | 9.4% | ||
| Q2 24 | 13.6% | 12.2% |
净利率AMRXLBRT
| Q1 26 | — | 2.2% | ||
| Q4 25 | 4.3% | 1.3% | ||
| Q3 25 | 0.3% | 4.5% | ||
| Q2 25 | 3.1% | 6.8% | ||
| Q1 25 | 1.8% | 2.1% | ||
| Q4 24 | -4.3% | 5.5% | ||
| Q3 24 | -0.0% | 6.5% | ||
| Q2 24 | 0.9% | 9.3% |
每股收益（稀释后）AMRXLBRT
| Q1 26 | — | $0.14 | ||
| Q4 25 | $0.10 | $0.08 | ||
| Q3 25 | $0.01 | $0.26 | ||
| Q2 25 | $0.07 | $0.43 | ||
| Q1 25 | $0.04 | $0.12 | ||
| Q4 24 | $-0.10 | $0.31 | ||
| Q3 24 | $0.00 | $0.44 | ||
| Q2 24 | $0.02 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $699.1M |
| 总债务越低越好 | $2.6B | $7.1M |
| 股东权益账面价值 | $-70.8M | $1.9B |
| 总资产 | $3.7B | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资AMRXLBRT
| Q1 26 | — | $699.1M | ||
| Q4 25 | $282.0M | $27.6M | ||
| Q3 25 | $201.2M | $13.5M | ||
| Q2 25 | $71.5M | $19.6M | ||
| Q1 25 | $59.2M | $24.1M | ||
| Q4 24 | $110.6M | $20.0M | ||
| Q3 24 | $74.0M | $23.0M | ||
| Q2 24 | $43.8M | $30.0M |
总债务AMRXLBRT
| Q1 26 | — | $7.1M | ||
| Q4 25 | $2.6B | $246.6M | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | $190.5M | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXLBRT
| Q1 26 | — | $1.9B | ||
| Q4 25 | $-70.8M | $2.1B | ||
| Q3 25 | $-109.5M | $2.1B | ||
| Q2 25 | $-112.1M | $2.0B | ||
| Q1 25 | $-131.7M | $2.0B | ||
| Q4 24 | $-109.3M | $2.0B | ||
| Q3 24 | $-93.4M | $2.0B | ||
| Q2 24 | $-57.5M | $1.9B |
总资产AMRXLBRT
| Q1 26 | — | $4.4B | ||
| Q4 25 | $3.7B | $3.6B | ||
| Q3 25 | $3.6B | $3.5B | ||
| Q2 25 | $3.4B | $3.4B | ||
| Q1 25 | $3.4B | $3.4B | ||
| Q4 24 | $3.5B | $3.3B | ||
| Q3 24 | $3.5B | $3.3B | ||
| Q2 24 | $3.5B | $3.2B |
负债/权益比AMRXLBRT
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | — |
| 自由现金流经营现金流 - 资本支出 | $108.5M | — |
| 自由现金流率自由现金流/营收 | 13.3% | — |
| 资本支出强度资本支出/营收 | 2.7% | 13.1% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | — |
8季度趋势，按日历期对齐
经营现金流AMRXLBRT
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $195.4M | ||
| Q3 25 | $118.5M | $51.5M | ||
| Q2 25 | $83.8M | $170.6M | ||
| Q1 25 | $7.4M | $192.1M | ||
| Q4 24 | $118.1M | $177.3M | ||
| Q3 24 | $141.8M | $244.5M | ||
| Q2 24 | $39.7M | $248.2M |
自由现金流AMRXLBRT
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $-10.0M | ||
| Q3 25 | $106.2M | $-67.2M | ||
| Q2 25 | $61.0M | $33.1M | ||
| Q1 25 | $-5.8M | $58.2M | ||
| Q4 24 | $102.9M | $-26.2M | ||
| Q3 24 | $124.8M | $77.9M | ||
| Q2 24 | $29.0M | $112.2M |
自由现金流率AMRXLBRT
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | -1.0% | ||
| Q3 25 | 13.5% | -7.1% | ||
| Q2 25 | 8.4% | 3.2% | ||
| Q1 25 | -0.8% | 6.0% | ||
| Q4 24 | 14.1% | -2.8% | ||
| Q3 24 | 17.8% | 6.8% | ||
| Q2 24 | 4.1% | 9.7% |
资本支出强度AMRXLBRT
| Q1 26 | — | 13.1% | ||
| Q4 25 | 2.7% | 19.8% | ||
| Q3 25 | 1.6% | 12.5% | ||
| Q2 25 | 3.2% | 13.2% | ||
| Q1 25 | 1.9% | 13.7% | ||
| Q4 24 | 2.1% | 21.6% | ||
| Q3 24 | 2.4% | 14.6% | ||
| Q2 24 | 1.5% | 11.7% |
现金转化率AMRXLBRT
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 14.28× | ||
| Q3 25 | 50.00× | 1.20× | ||
| Q2 25 | 3.74× | 2.40× | ||
| Q1 25 | 0.61× | 9.55× | ||
| Q4 24 | — | 3.42× | ||
| Q3 24 | — | 3.31× | ||
| Q2 24 | 6.62× | 2.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
LBRT
暂无分部数据
